The risk of suicidal actions among patients who receive isotretinoin may be lower than previously understood, according to a recent meta-analysis published by Tan et al in JAMA Dermatology. Investigators explained that isotretinoin use has long been considered a potential risk factor for psychiatric disorders. In the analysis, the investigators used the PubMed, Embase, Web of Science, and Scopus databases to examine outcomes from 25 randomized and observational studies involving 1.6 million patients aged 16 to 38 years who received isotretinoin. They found that the risk of depression among isotretinoin users was 3.83%; whereas the 1-year absolute risk of completed suicide, suicide attempts, suicidal ideation, and self-harm behaviors was less than 0.5%. Compared with those who didn’t receive isotretinoin, patients who did receive the agent were less likely to attempt suicide within 2 years (risk ratio [RR] = 0.92, 95% confidence interval [CI] = 0.84–1.00), 3 years (RR = 0.86, 95% CI = 0.77–0.95), and 4 years (RR = 0.85, 95% CI = 0.72–1.00) following treatment. Further, studies that included older patients were more likely to demonstrate a lower absolute risk of depression, and those that included male patients were more likely to demonstrate a higher absolute risk of completed suicide after 1 year. The investigators concluded that compared with individuals in the general population, the use of isotretinoin was not associated with an increased relative risk of all psychiatric disorders or suicide up to 4 years posttreatment.